Camrelizumab
- Generic Name
- Camrelizumab
- Drug Type
- Biotech
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant
- Conditions
- Hepatocellular CarcinomaLiver Transplant
- Interventions
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 120
- Registration Number
- NCT04035876
- Locations
- 🇨🇳
The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang, China
SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04014101
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China
PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma
- First Posted Date
- 2019-05-20
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 30
- Registration Number
- NCT03955354
- Locations
- 🇨🇳
Guo Jun, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, China
SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT03950271
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT03945604
- Locations
- 🇨🇳
Beijing Cancer Hosptial, Beijing, Beijing, China
Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal Cancer
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT03912857
- Locations
- 🇨🇳
Cancer center of Sun Yat-sen University, Guangzhou, Guangdong, China
Neoadjuvant Immunotherapy for Resectable Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 25
- Registration Number
- NCT03878472
- Locations
- 🇨🇳
Qilu hospital of Shandong univertisy, Jinan, Shandong, China
A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT03871855
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer
- Conditions
- Recurrent Cervical CarcinomaMetastatic Cervical Cancer
- Interventions
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 45
- Registration Number
- NCT03816553
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳The First affiliated Hospital of Sun Yat-sen University, Guanzhou, Guangdong, China
🇨🇳Guangzhou Panyu Central Hospital, Guangzhou, Guangdong, China
A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCC
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Target Recruit Count
- 725
- Registration Number
- NCT03817658
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.